La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

ImpediMed Gestione

Gestione criteri di controllo 0/4

ImpediMed's Il CEO è Parmjot Bains, nominato in Jan2024, ha un mandato di meno di un anno. possiede direttamente 0.001% delle azioni della società, per un valore di A$ 1.21K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 0.8 anni e 0.8 anni.

Informazioni chiave

Parmjot Bains

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	0.001%
Durata media del management	less than a year
Durata media del Consiglio di amministrazione	less than a year

Aggiornamenti recenti sulla gestione

Recent updates

Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

Sep 28

We're Not Worried About ImpediMed's (ASX:IPD) Cash Burn

Jun 10

A Look At The Fair Value Of ImpediMed Limited (ASX:IPD)

Feb 01

We Think ImpediMed (ASX:IPD) Can Afford To Drive Business Growth

Aug 25

Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

Apr 06

Analysts Expect Breakeven For ImpediMed Limited (ASX:IPD) Before Long

Feb 12

AMMINISTRATORE DELEGATO

Parmjot Bains

less than a year

Mandato

Dr. Parmjot Bains, M.D. serves as Managing Director at ImpediMed Limited from January 08, 2023 and serves as its CEO since July 01, 2024 and serves as its Director from 2024 and served as its Chief Executi...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Parmjot Bains	MD, CEO & Director	less than a year	Nessun dato	0.0011% A$ 1.2k
McGregor Grant	Chief Financial & Operating Officer and Executive Director	less than a year	Nessun dato	0.10% A$ 115.1k
Dennis Schlaht	Senior Vice President of R&D and Technology	no data	AU$704.20k	Nessun dato
Tim Benkovic	Senior Vice President of Sales & Customer Success	less than a year	Nessun dato	Nessun dato
Andrew Grant	Executive Director and VP of Product Development & Customer Solutions	less than a year	Nessun dato	0.020% A$ 22.4k
Steven Chen	Chief Medical Center	less than a year	Nessun dato	Nessun dato
Leanne Ralph	Company Secretary	9.6yrs	Nessun dato	Nessun dato
Walton Taylor	Medical Director	14.4yrs	Nessun dato	Nessun dato

0.8yrs

Durata media

Gestione esperta: Il team dirigenziale di IPD non è considerato esperto (durata media 0.8 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Parmjot Bains	MD, CEO & Director	less than a year	Nessun dato	0.0011% A$ 1.2k
McGregor Grant	Chief Financial & Operating Officer and Executive Director	less than a year	Nessun dato	0.10% A$ 115.1k
Andrew Grant	Executive Director and VP of Product Development & Customer Solutions	less than a year	Nessun dato	0.020% A$ 22.4k
Christine Emmanuel-Donnelly	Independent Non-Executive Chair	less than a year	Nessun dato	0.019% A$ 21.8k
Janelle Delaney	Independent Non-Executive Director	less than a year	Nessun dato	0.19% A$ 220.1k
Fiona Bones	Non-Executive Director	less than a year	Nessun dato	0.0040% A$ 4.5k

0.8yrs

Durata media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di IPD non è considerato esperto (durata media del mandato 0.8 anni), il che suggerisce un nuovo consiglio.

ImpediMed Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

ImpediMed Limited Appoints Parmjot Bains as CEO on an ongoing basis

ImpediMed Limited Appoints Fiona Bones as A Non-Executive Director

Independent Non-Executive Director recently bought AU$50k worth of stock

Independent Non-Executive Director recently bought AU$100k worth of stock

Independent Non-Executive Director recently bought AU$90k worth of stock

High number of new and inexperienced directors

Recent updates

Forecast to breakeven in 2026

ImpediMed Limited Appoints Parmjot Bains as CEO on an ongoing basis

We Think ImpediMed (ASX:IPD) Can Afford To Drive Business Growth

ImpediMed Limited Appoints Fiona Bones as A Non-Executive Director

New minor risk - Market cap size

Independent Non-Executive Director recently bought AU$50k worth of stock

ImpediMed Limited to Report Q3, 2024 Results on Apr 30, 2024

Price target decreased by 9.6% to AU$0.18

ImpediMed to Present Chronic Breast Cancer-Related Lymphedema Study Results at American Society of Breast Surgeons Annual Meeting

Independent Non-Executive Director recently bought AU$100k worth of stock

ImpediMed (ASX:IPD) Is In A Good Position To Deliver On Growth Plans

Consensus revenue estimates decrease by 13%

Independent Non-Executive Director recently bought AU$90k worth of stock

Price target decreased by 12% to AU$0.19

No longer forecast to breakeven

High number of new and inexperienced directors

New minor risk - Share price stability

ImpediMed Limited to Report First Half, 2024 Results on Feb 27, 2024

Independent Non-Executive Director recently bought AU$135k worth of stock

Companies Like ImpediMed (ASX:IPD) Are In A Position To Invest In Growth

Consensus revenue estimates decrease by 20%

ImpediMed Limited Announces CFO Changes

Price target decreased by 16% to AU$0.23

Price target increased by 21% to AU$0.27

ImpediMed Limited to Report Q1, 2024 Results on Oct 31, 2023

ImpediMed Limited, Annual General Meeting, Nov 30, 2023

High number of new directors

ImpediMed Limited Announce the Appointment of Steven Chen as Chief Medical Officer

Consensus revenue estimates decrease by 23%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Full year 2023 earnings: EPS and revenues miss analyst expectations

ImpediMed Limited, Annual General Meeting, Sep 28, 2023

Price target increased by 27% to AU$0.21

ImpediMed Limited to Report Q4, 2023 Results on Jul 24, 2023

Is ImpediMed (ASX:IPD) In A Good Position To Deliver On Growth Plans?

ImpediMed Limited Appoints Daniel Sharp as Director

Executive Director recently bought AU$144k worth of stock

Independent Non-Executive Chairman recently bought AU$82k worth of stock

No longer forecast to breakeven

MD, CEO & Director recently bought AU$52k worth of stock

MD, CEO & Director recently bought AU$54k worth of stock

Price target increased by 25% to AU$0.18

We Think ImpediMed (ASX:IPD) Needs To Drive Business Growth Carefully

MD, CEO & Director recently bought AU$64k worth of stock

First half 2023 earnings released: AU$0.01 loss per share (vs AU$0.006 loss in 1H 2022)

Price target decreased by 7.7% to AU$0.17

ImpediMed Limited to Report Q2, 2023 Results on Jan 30, 2023

ImpediMed Limited Presents New Data at 2022 San Antonio Breast Cancer Symposium Shows Early Detection Using L-Dex and Intervention Improves Lymphedema Progression-Free Survival

Impedimed Limited Announces CEO Changes

ImpediMed Limited Announces Management Changes

Less than half of directors are independent

Executive Director & Interim CEO recently bought AU$164k worth of stock

Less than half of directors are independent

ImpediMed Limited Announces Current Data Support Early Detection and Intervention to Reduce Rates of Breast Cancer Related Lymphedema

ImpediMed Limited to Report Q1, 2023 Results on Oct 19, 2022

ImpediMed Expands Use of SOZO in Leading Cancer Centers Focused on Reducing the Impact of Lymphedema after Breast Cancer

ImpediMed Announces U.S. Launch of Lymphedema Prevention Program with GenesisCare a Global Organization Dedicated to Care of Cancer Patients

Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

Consensus forecasts updated

Price target decreased to AU$0.18

ImpediMed Limited Announces Board Changes

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

ImpediMed Limited, Annual General Meeting, Oct 26, 2022

Price target decreased to AU$0.22

ImpediMed Limited Announces Executive Changes

Less than half of directors are independent

ImpediMed Limited Announces Resignation of Richard Carreon as Managing Director

We're Not Worried About ImpediMed's (ASX:IPD) Cash Burn

ImpediMed Limited Announces Release of the New Version 4.1 Software for the SOZO Digital Health Platform